Hyperphosphatemia affects most patients with advanced chronic kidney disease (CKD) and contributes to substantial morbidity and mortality, yet the majority of patients on dialysis do not achieve and maintain phosphate control. Several treatment options, including those with novel mechanisms of action, are now available to lower phosphate levels in affected patients, providing an opportunity to improve outcomes through individualized therapy. With the expanding armamentarium of phosphate-lowering therapies, it is more important than ever to stay abreast of the latest clinical evidence and strategies for optimizing phosphate management in this high-risk population Don’t miss the chance to watch two leading nephrologists discuss the importance of hyperphosphatemia management and key characteristics of phosphate-lowering therapies, including their different mechanisms of action illustrated via video animation. Listen in as they review the most recent safety and efficacy data for these therapies and share their expert approaches to designing patient-centered treatment plans to reduce the risks of CKD mineral bone disorder.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/navigating-evolving-landscape-phosphate-lowering-therapies-hyperphosphatemia-ckd
- Start Date: 2024-12-31 06:00:00
- End Date: 2024-12-31 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Ardelyx, Inc. - Amount: 45000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all